||Last Updated: Nov 17th, 2006 - 22:35:04
Genomic signatures to guide the use of chemotherapeutics
Scientists at Duke University's Institute for Genome Sciences & Policy have developed a panel of genomic tests that analyzes the unique molecular traits of a cancerous tumor and determines which chemotherapy will most aggressively attack that patient's cancer.
Oct 23, 2006, 18:59
CDK2/FOXO1 as drug target to Prevent Tumors
Mayo Clinic researchers have found that a protein that initiates a "quality control check" during cell division also directs cell death for those cells damaged during duplication. This knowledge represents a potential "bulls eye" for targeting anti-tumor drugs. The findings appear in the current issue of Science.
Oct 13, 2006, 01:11
Gleevec can be toxic to the heart
Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets in the cancer cell, can be dangerous to the heart. Not only that, but other similarly based drugs – called tyrosine kinase inhibitors – could lead to heart problems as well, say researchers at the Center for Translational Medicine at Jefferson Medical College in Philadelphia.
Jul 24, 2006, 19:27
AS101 protects the testis from the effects of paclitaxel
It may be possible to protect the testes of cancer patients against the loss of fertility caused by chemotherapy, a scientist told the 22nd annual conference of the European Society of Human Reproduction and Embryology in Prague, Czech Republic on Tuesday 20 June 2006. Mr. Alon Carmely from Bar-Ilan University, Ramat Gan, Israel, said that his work showed for the first time that the injection of a drug that enhances the immune system could protect the testis from the effects of paclitaxel (Taxol), a widely used chemotherapy drug.
Jun 20, 2006, 21:30
Fibrasorb - New device that could cut chemotherapy deaths
A new method of delivering chemotherapy to cancer patients without incurring side effects such as hair loss and vomiting is being developed. The method, produced at the University of Bath, England, involves using tiny fibres and beads soaked in the chemotherapy drug which are then implanted into the cancerous area in the patient's body.
Apr 3, 2006, 07:21
Serendipity versus planning - cancer drugs of the future?
New anticancer drugs are usually developed specially for the job, but occasionally they are borrowed from another field of medicine, and applied speculatively in cancer. Tamoxifen was designed as an anti-oestrogen, based on the observation that at least a third of breast cancers depend on female sex hormones such as oestrogen for survival. Tamoxifen has shown to be an exceptionally effective molecule in cancer treatment; It was never planned to be a preventive agent, but so it has proved to be! It is now licensed to be used to prevent breast cancer in certain women at high risk of the disease.
Mar 27, 2006, 04:29
Sunitinib Approved for Gastrointestinal Stromal Tumors (GIST) and Kidney Cancer
The Food and Drug Administration (FDA) today announced approval of Sutent (sunitinib), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer. Today's action marks the first time the agency has approved a new oncology product for two indications simultaneously.
Jan 28, 2006, 12:29
Celecoxib able to control chemotherapy resistant tumor cells
A close structural relative of the celebrated COX-2 inhibitor celecoxib (brand name: Celebrex) is a potent tumor fighter, able to wipe out tumor cells that are resistant to conventional chemotherapies, according to an interdisciplinary team of researchers from the University of Southern California.
Aug 30, 2005, 19:23
Inhibiting EAT-2 with medications could boost NK cell activity
Dr. André Veillette, a researcher at the Institut de recherches cliniques de Montréal (IRCM), and his team will publish in the upcoming issue of the prestigious journal Nature Immunology of Nature Publishing Group, a discovery that could significantly advance the treatment of cancers and infectious diseases. Current treatments frequently achieve only limited results with these types of diseases, which affect hundreds of thousands of Canadians.
Aug 29, 2005, 22:57
Some Cancer Patients Treated With Cetuximab May Require Magnesium Supplementation
Some cancer patients being treated with cetuximab (Erbitux) may develop abnormally low blood levels of magnesium (hypomagnesemia) and require supplementation, according to a new study.
Aug 19, 2005, 04:59
Tie-1 significantly inhibits tumor progression in murine models
Dyax Corp. (Nasdaq: DYAX) announced today its presentation at the Drug Discovery Technology Conference (Boston Convention Center), highlighting the Company's discovery that antibody targeting of Tie-1 leads to the inhibition of primary tumor growth in murine models.
Aug 11, 2005, 23:06
Orphan Drug Application Filed for NOV-002 for Treating Refractory Ovarian Cancer
Novelos Therapeutics, Inc. (OTC BB: NVLT), a biotech company focusing on oxidized glutathione for use in fighting cancer and hepatitis, today announced that it has filed an orphan drug application with the U.S. FDA for the Company's lead compound, NOV-002. The application focuses on the investigation of combination therapy of NOV-002 with standard chemotherapy for treating refractory (chemotherapy resistant) ovarian cancer. A response from the FDA is expected by mid August.
Jun 17, 2005, 09:56
Treating 'chemobrain' by using dexmethyphenidate (d-MPH)
Patients who take medication for cancer often find themselves with a new problem when their treatment ends.
It's called "chemobrain," a common consequence of chemotherapy that causes memory problems, confusion and difficulty in concentrating.
Jun 8, 2005, 13:00
A bioadhesive miconazole tablet is an effective way to treat oropharyngeal candidiasis
A bioadhesive tablet containing the antifungal drug miconazole is an effective and convenient means of treating oropharyngeal candidiasis, which is the most frequently occurring infection in head and neck cancer patients undergoing radiation therapy, scientists report today at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.
Jun 7, 2005, 12:01
p53-based Targets as Novel Cancer Treatment Strategies
ADVEXIN(R) and INGN 225, investigational cancer therapies currently being evaluated in Phase 3 and Phase 2 trials, respectively, by Introgen Therapeutics, Inc. , were highlighted today in a special session, titled "The Clinical Trial Data on Ad-p53 Gene Therapy of Cancer" at the American Society of Gene Therapy 8th Annual Meeting (ASGT).
Jun 3, 2005, 10:22
Tarvacin Plus Docetaxel Significantly Inhibits Breast Tumor Growth
The published report shows that 3G4 (a murine equivalent of the company's Tarvacin(TM) monoclonal antibody) in combination with docetaxel results in a 93% inhibition of human breast cancer growth in mouse models. The researchers found that docetaxel increases the exposure of the 3G4 target on tumor blood vessels but not healthy tissue. Patient enrollment in a Tarvacin(TM) Phase 1 clinical trial for the treatment of all solid tumors, including breast cancer, is expected to commence this month at three clinical sites.
May 27, 2005, 18:03
Capecitabine as a Convenient Oral Treatment for Colon Cancer Patients
Data presented this week further strengthens the wealth of evidence showing that Xeloda(R) (capecitabine), an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting.
May 23, 2005, 10:28
Gemcitabine Based Regimens Improve Quality of Life in Non-Small Cell Lung Cancer
Data presented today(1,2,3) from ongoing clinical trials show that therapies based on Eli Lilly and Company's (LLY) Gemzar(R) (gemcitabine, HCl) administered prior to surgery have a positive impact on survival, tumor shrinkage and quality of life among patients with early-stage non-small cell lung cancer (NSCLC).
May 18, 2005, 09:49
FDA Accepts Sorafenib into Pilot 1 Program
Bayer Pharmaceuticals Corporation (NYSE: BAY - News) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced that sorafenib (formerly BAY 43-9006) has been accepted into the U.S. Food and Drug Administration's (FDA) Pilot 1 Program for continuous marketing applications.
May 4, 2005, 21:43
IND Filed for CRA-024781, a Novel Histone Deacetylase Inhibitor
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CRA-024781, a novel histone deacetylase (HDAC) inhibitor. Pending clearance by the FDA, Celera Genomics plans to initiate Phase 1 clinical trials.
May 3, 2005, 09:50
IND Filed for XL820, a Novel Anticancer Compound
Exelixis, Inc. (Nasdaq: EXEL - News) has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL820. This novel small molecule anticancer compound potently inhibits receptor tyrosine kinases (RTKs) implicated in tumor proliferation and vascularization. XL820 is the fifth compound to advance in clinical development from Exelixis' internal drug discovery capabilities. Pending clearance by the FDA, Exelixis intends to initiate a Phase I clinical trial for XL820.
Apr 26, 2005, 12:07
CoFactor : A Folate-Based Biomodulator Drug Starts Phase III Trial for the Treatment of Metastatic Colorectal Cancer
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it has received clearance from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) to initiate a Phase III pivotal clinical trial with CoFactor for the treatment of metastatic colorectal cancer. CoFactor is the Company's biomodulator designed to enhance the activity of the widely used cancer drug 5-fluorouracil (5-FU).
Apr 26, 2005, 12:00
Role of 2-methoxyestradiol in Treating Various Types of Cancer
EntreMed, Inc. today announced the results of multiple in vitro and in vivo preclinical studies confirming the mechanisms-of-action for 2-methoxyestradiol (2ME2 or Panzem(R)) in treating various types of cancer. The results from these studies, conducted by EntreMed researchers and their collaborators, were presented at the 96th Annual Meeting of the American Association for Cancer Research being held this week in Anaheim, California.
Apr 21, 2005, 14:09
FDA Gives ANDA Status to Vinorelbine for its Indication in Unresectable, Advanced Non Small Cell Lung Cancer
American Pharmaceutical Partners, Inc. (Nasdaq: APPX - News) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of Vinorelbine Tartrate Injection, 10 mg (base)/mL, the generic equivalent of GlaxoSmithKline's Navelbine®. According to IMS, sales of vinorelbine tartrate were approximately $61 million in 2004. The company expects to commence marketing this product in the near term.
Apr 20, 2005, 09:17
GTI-2040 : A Novel Antisense Drug Improves Efficacy of a Number of Chemotherapies
Lorus Therapeutics Inc., a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced that its wholly owned subsidiary GeneSense Technologies Inc. has received notice from the European Patent Office of its intention to grant the GeneSense application for a patent of its novel antisense drug GTI-2040.
Mar 22, 2005, 08:32
Temozolomide Brings New Hope for Glioblastoma Patients
A large international study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) in collaboration with the National Cancer Institute of Canada (NCIC) Clinical Trials Group demonstrated that the addition of a novel chemotherapy agent, Temozolomide (brand name: Temodal(R)) to radiation therapy increases survival in patients suffering from glioblastoma, a very aggressive form of a brain tumour. Further, molecular analyses of the tumour allowed for the identification of those patients most likely to benefit from this type of treatment. The findings are leading to a new standard of care for patients with this fast growing and devastating cancer. The results of this landmark trial are published in two companion papers in this weeks' edition of the New England Journal of Medicine.
Mar 10, 2005, 07:40
A Novel RAF kinase and VEGFR Inhibitor as Single Agent Therapy for Advanced Hepatocellular Carcinoma - Under Trial
BAY 43-9006, a novel investigational drug candidate, has demonstrated anti-proliferative and anti-angiogenic properties - two important anticancer activities. In preclinical models, BAY 43-9006 inhibited tumor cell proliferation by targeting the RAF/MEK/ERK signaling pathway at the level of RAF kinase.
Mar 9, 2005, 08:37
A Novel Murine Monoclonal Antibody, 3G4 , Targets Phospholipids to Treat Cancer
Peregrine Pharmaceuticals, Inc.announced today the publication of data in 'Clinical Cancer Research' demonstrating significant anti-tumor activity in various tumor models using the murine monoclonal antibody 3G4, an equivalent of the company's Tarvacin(TM), that recognizes anionic phospholipids exposed on the surface of tumor blood vessels. These studies were performed by researchers at University of Texas Southwestern Medical Center at Dallas.
Mar 8, 2005, 14:43
Pegfilgrastim Significantly Reduces the Incidence of Febrile Neutropenia in Patients on Chemotherapy
The phase 3 study showed that administering pegfilgrastim beginning in the first and subsequent cycles of chemotherapy reduced the incidence of febrile neutropenia (low white blood cell count with fever), a serious complication of cancer chemotherapy typically associated with infection, by more than 90 percent.
Feb 27, 2005, 13:43
New insight into how tumor cells can become resistant to anti-cancer therapy
The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically "jump" or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro. According to the authors, the research is the first to demonstrate that a protein transferred between cells retains its function long enough to allow the recipient cells to survive potentially toxic drug concentrations and ultimately develop intrinsic resistance.
Jan 18, 2005, 12:46